Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Shares Issued (2018 - 2023)

VYNE Therapeutics' Shares Issued history spans 6 years, with the latest figure at $156000.0 for Q1 2023.

  • For Q1 2023, Shares Issued fell 89.98% year-over-year to $156000.0; the TTM value through Dec 2023 reached $156000.0, down 89.6%, while the annual FY2023 figure was $156000.0, 89.6% down from the prior year.
  • Shares Issued reached $156000.0 in Q1 2023 per VYNE's latest filing, up from $29000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $73.1 million in Q1 2021 to a low of -$75.5 million in Q4 2021.
  • Average Shares Issued over 5 years is $5.5 million, with a median of $91000.0 recorded in 2020.
  • Peak YoY movement for Shares Issued: surged 4900.0% in 2020, then plummeted 222.83% in 2021.
  • A 5-year view of Shares Issued shows it stood at $13.7 million in 2019, then surged by 349.58% to $61.5 million in 2020, then tumbled by 222.83% to -$75.5 million in 2021, then soared by 100.04% to $29000.0 in 2022, then soared by 437.93% to $156000.0 in 2023.
  • Per Business Quant, the three most recent readings for VYNE's Shares Issued are $156000.0 (Q1 2023), $29000.0 (Q4 2022), and -$86000.0 (Q2 2022).